Norges Bank
CSTL icon

Norges Bank’s Castle Biosciences CSTL Stock Holding History

Norges Bank’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-61,600
Closed -$1.4M – 2034
2023
Q1 		$1.4M Sell
61,600
-69,600
-53% -$1.7M ﹤0.01% 1964
2022
Q4 		$3.09M Sell
131,200
-5,400
-4% -$125K ﹤0.01% 1897
2022
Q3 		$3.56M Buy
+136,600
New +$3.83M ﹤0.01% 1827

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank's CSTL Position: Q2 2023 in Review

Norges Bank sold out of Castle Biosciences (CSTL) in Q2 2023, closing a stake of 61,600 shares — an estimated $1.4M sold.

Norges Bank first reported a position in CSTL in Q3 2022 and held it in 3 quarters. The position peaked at $3.56M in Q3 2022. 130 funds tracked by Wall St. Rank hold CSTL as of Q2 2023.

  • Norges Bank reported no remaining Castle Biosciences position as of Q2 2023 after selling out during the quarter.
  • Norges Bank sold 61,600 Castle Biosciences shares in Q2 2023, an estimated $1.4M.
  • Norges Bank first reported a position in Castle Biosciences in Q3 2022 and held it in 3 quarters.
  • Norges Bank's Castle Biosciences position peaked at $3.56M in Q3 2022.
  • 130 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2023.

Based on Norges Bank's 13F filing for Q2 2023, filed 14 Aug 2023.